Adverse events1,410

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,410

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal pain	Gastrointestinal disorders	Phase I, All Histologies, Lenalidomide 15 mg	1	8
other	Abdominal pain	Gastrointestinal disorders	Phase I, All Histologies, Lenalidomide 20 mg	1	3
other	Abdominal pain	Gastrointestinal disorders	Phase I, All Histologies, Lenalidomide 25 mg	1	6
other	Abdominal pain	Gastrointestinal disorders	Phase II, Diffuse Large B-Cell Subtype	9	39
other	Abdominal pain	Gastrointestinal disorders	Phase II, Follicular Subtype	1	15
other	Abdominal pain	Gastrointestinal disorders	Phase II, Lymphoma NOS	7	39
other	Alkaline aminotransferase increase	Investigations	Phase I, All Histologies, Lenalidomide 15 mg	4	8
other	Alkaline aminotransferase increase	Investigations	Phase I, All Histologies, Lenalidomide 20 mg	1	3
other	Alkaline aminotransferase increase	Investigations	Phase I, All Histologies, Lenalidomide 25 mg	2	6
other	Alkaline aminotransferase increase	Investigations	Phase II, Diffuse Large B-Cell Subtype	12	39
other	Alkaline aminotransferase increase	Investigations	Phase II, Follicular Subtype	7	15
other	Alkaline aminotransferase increase	Investigations	Phase II, Lymphoma NOS	21	39
other	Alkaline phosphatase increased	Investigations	Phase I, All Histologies, Lenalidomide 15 mg	2	8
other	Alkaline phosphatase increased	Investigations	Phase I, All Histologies, Lenalidomide 20 mg	1	3
other	Alkaline phosphatase increased	Investigations	Phase I, All Histologies, Lenalidomide 25 mg	1	6
other	Alkaline phosphatase increased	Investigations	Phase II, Diffuse Large B-Cell Subtype	9	39
other	Alkaline phosphatase increased	Investigations	Phase II, Follicular Subtype	6	15
other	Alkaline phosphatase increased	Investigations	Phase II, Lymphoma NOS	17	39
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Phase I, All Histologies, Lenalidomide 15 mg	2	8
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Phase I, All Histologies, Lenalidomide 20 mg	0	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01076543/events

API reference For AI assistants

Adverse events1,410

Sources 3

Read this list from software.